PSB-1737

PSB-1737 is a human-selective GPR17 agonist with an EC50 for human GPR17 of 270 nM, and its activity on murine GPR17 is relatively weak (EC50 > 10 μM) . PSB-1737 shows no significant inhibition at the glycine binding site of NMDA receptors, and has no significant agonistic or antagonistic activity on P2Y receptor subtypes. PSB-1737 can be used in demyelinating diseases (such as multiple sclerosis) or inflammatory-related anemia[1].

Product Specifications

CAS Number

[139896-80-3]

UNSPSC

12352005

Target

Orphan GPCR

Related Pathways

GPCR/G Protein

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology; Cardiovascular Disease

Smiles

O=C(C1=C(CCC(O)=O)C2=C(C=C(C=C2)OC3=CC=CC=C3)N1)O

Molecular Formula

C18H15NO5

Molecular Weight

325.32

References & Citations

[1]Baqi Y, et al. 3- (2-Carboxyethyl) indole-2-carboxylic Acid Derivatives: Structural Requirements and Properties of Potent Agonists of the Orphan G Protein-Coupled Receptor GPR17. J Med Chem. 2018 Sep 27;61 (18) :8136-8154.